Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the metformin market?

The market size for metformin has experienced significant expansion in the past years. A surge from $4.17 billion in 2024 to $4.48 billion in 2025 is expected, reflecting a compound annual growth rate (CAGR) of 7.4%. The growth in the previous period is largely accredited to an increase in the occurrence of diabetes, enhancement in diabetes awareness, and a rise in healthcare expenditure.

What will be the metformin market size in the future?

A robust expansion in the metformin market is predicted in the forthcoming years, with its value expected to reach $5.88 billion by 2029, alongside a compound annual growth rate (CAGR) of 7.1%. The projected growth in the forecasted timeframe is chiefly due to the development in emerging markets, rising awareness, and usage of metformin, an aging population, expiration of patents and generic competition, surge in demand for combined therapies, heightened understanding of side effects, and security concerns. Key trends anticipated during the forecast period encompass the introduction of novel products, lifestyle modifications, research and development initiatives, enhanced partnerships, and advancements in manufacturing technology.

Get your metformin market report here!

https://www.thebusinessresearchcompany.com/report/metformin-global-market-report

What main drivers are fueling expansion in the metformin market?

The escalating incidence of diabetes is anticipated to stimulate the expansion of the metformin market in the coming years. Diabetes, a health problem, arises when the pancreas fails to produce sufficient insulin or when the body struggles to utilize the insulin it generates efficiently. Several factors contribute to the prevalence of diabetes, including an obesity epidemic, genetic predispositions, changes in lifestyle, limited availability of healthcare, and exposure to specific toxins. Metformin plays a key role in managing type 2 diabetes by reducing blood sugar levels, promoting weight loss, improving insulin sensitivity, and potentially offering other cardiovascular benefits. Diabetes Canada, a non-profit organization based in Canada, noted in February 2023 that the projected prevalence of diabetes in Canada is expected to inflate from 2,409,000 cases (15% of the population) in 2023 to 3,009,000 cases (17% of the population) by 2033. As a result, the rise in diabetes prevalence is fuelling the metformin market’s growth.

What key areas define the segmentation of the global metformin market?

The metformin market covered in this report is segmented –

1) By Product Type: Standard-Release Tablets, Slow-Release Tablets

2) By Dosage Type: 500MG, 750MG, 850MG, 1G

3) By End-user: Clinics, Hospitals, Homecare, Other End-Users

Subsegments:

1) By Standard-Release Tablets: 500 Mg, 850 Mg, 1000 Mg

2) By Slow-Release Tablets: 500 Mg, 750 Mg, 1000 Mg

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16475&type=smp

Who are the dominant players expanding their reach in the metformin market?

Major companies operating in the metformin market are Wockhardt Limited, Aarti Drugs, Abhilash Chemicals Private Limited, Farmhispania, Rochem International Inc., Jai Radhe Sales, Chr. Olesen Group, Aspire Lifesciences Pvt. Ltd., Ria Lifesciences Pvt. Ltd., Shree Sadguru, LGM Pharma, HRV Global Life Sciences, Octavius Pharma Pvt. Ltd., USV Private Limited, Zeon Pharma Industries India Pvt. Ltd., Atman Pharmaceuticals, Aastrid International Pvt. Ltd., Abhilasha Pharma, Anwita Drugs & Chemicals Pvt. Ltd., IOL Chemicals and Pharmaceuticals, Gangwal Healthcare, Granules India Limited, Alekhya Drugs Pvt. Ltd, Angels Pharma India Private Limited, Auro Laboratories Ltd.

How are evolving market trends shaping metformin Strategies?

The metformin market is dominated by leading companies striving to produce innovative diabetes drugs such as the triple-drug FDC, to consolidate their market standing. A triple-drug Fixed Dose Combination (FDC) refers to one single tablet or capsule comprising three unique antidiabetic drugs. This combination is meticulously designed to enhance blood sugar management and improve overall glycemic control for type 2 diabetes patients. In October 2023, India’s Glenmark Pharmaceuticals introduced the first-ever triple-drug fixed-dose combination (FDC) of teneligliptin, dapagliflozin, and metformin in India, branded as Zita DM. The Zita DM FDC contains teneligliptin (20 mg), dapagliflozin (10 mg), and a fixed dose of either 500 mg or 1000 mg of metformin SR. It is engineered to better the glycemic control in adults suffering from Type 2 diabetes, especially ones whose condition remains uncontrolled by metformin or require supplemental teneligliptin and dapagliflozin as separate medications.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16475

Which regions are emerging as leaders in the metformin market?

North America was the largest region in the metformin market in 2024. The regions covered in the metformin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Blood Glucose Meters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-glucose-meters-global-market-report

Metal And Mineral Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/metal-and-mineral-global-market-report

Vital Parameter Monitoring Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vital-parameter-monitoring-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: